Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?

Area of Science:

• Neurology
• Genetics
• Biotechnology

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder causing progressive muscle weakness and fatal complications.
• Current DMD treatments focus on symptom management, lacking a cure for the underlying genetic defect.

Purpose of the Study:

• To review the efficacy and safety of emerging Duchenne muscular dystrophy gene therapies as of 2024.
• To explore novel therapeutic strategies including utrophin upregulation and gene editing for DMD.

Main Methods:

• Evaluation of current gene replacement therapies, including FDA-approved treatments.
• Assessment of gene editing technologies like CRISPR-Cas9 for DMD.
• Review of strategies for delivering full-length or truncated dystrophin.

Main Results:

• Gene replacement therapy, exemplified by delandistrogene moxeparvovec, shows promise but requires safety enhancements.
• CRISPR-Cas9 therapies face regulatory and safety hurdles for clinical use.
• Emerging therapies aim to address genetic defects, with potential for utrophin upregulation and dystrophin restoration.

Conclusions:

• Optimizing gene therapy safety by understanding adverse events and patient variant selection is crucial.
• Targeting both skeletal and cardiac muscles is essential for effective DMD treatment.
• Further research is needed to overcome challenges in gene editing and full-length dystrophin delivery for DMD.